

Comments

The amendment to the Specification adds the priority claim for the present application; no new matter is being added. The amendment to the Specification also corrects inadvertent errors in the Specification.

The amendment to the Abstract brings the Abstract into compliance with USPTO rules. No new matter is being added.

The Claims are amended to bring the application into compliance with USPTO rules. Claims 1-5 were originally presented in the International Patent Application for this invention. Upon entry into the US during National Phase, a Preliminary Amendment was filed (on July 21, 2003) in which Claims 1-5 were cancelled and new Claims 6-11 were presented. Now, upon filing of this divisional application, Claims 6-11 are being cancelled and new Claims 12-17 are being added. Support for new Claims 12-17 can be found in Table 1 on page 11. No new matter is being added.

Please charge \$770 and any additional fees to Deposit Account 19-0134 in the name of Novartis.


Applicants request that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

Thomas Hoxie
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address. Thank you for your assistance with this matter.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7922


David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: October 2, 2003